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NAD(P)H:quinone oxidoreductase I reduces the
mutagenicity of DNA caused by NADPH:P450 reductase-
activated metabolites of benzo(a)pyrene quinones
P Joseph and AK Jaiswal
Department of Pharmacology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
Summary The role of microsomal NADPH:cytochrome P450 reductase (P450 reductase) and cytosolic NAD(P)H:quinone oxidoreductase 1
(NQO1 or DT-diaphorase) in the mutagenicity of benzo(a)pyrene-3,6-quinone (BP-3,6-Q) was studied using supF tRNA gene as the
mutational target. pUB3 carrying the supF tRNA gene upon transformation into the Escherichia coli ES87 cells exhibited a spontaneous
mutation frequency of 0.62 x 10-6. Chemical modification of the pUB3 DNA with BP-3,6-Q caused a fourfold increase in the mutation
frequency, compared with the spontaneous mutations. P450 reductase catalysed metabolic activation of BP-3,6-Q into reactive products
(semiquinone and reactive oxygen species), which caused a further increase in the mutation frequency to eighffold over spontaneous
mutations. Oxygen radical scavengers (SOD and catalase) blocked the P450 reductase-activated BP-3,6-Q-induced stimulation of mutations.
This indicates that redox cycling of the semiquinone leading to the generation of reactive oxygen species (ROS) was directly responsible for
the increased mutation frequency of P450 reductase-activated BP-3,6-Q. Analysis of the mutation spectra revealed that P450 reductase-
activated BP-3,6-Q showed a significantly higher preference for frameshift mutations, particularly deletions, compared with the spontaneous
mutations and the mutations generated by benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE). The single most frequently observed
mutation by P450 reductase-activated quinone (semiquinone + ROS) was deletion of a single guanosine. Among the base substitutions,
G:C -> T:A, G:C -+ A:T and G:C -- C:G were also noticed. Interestingly, NQO1 competed with P450 reductase and specifically prevented the
P450 reductase-activated BP-3,6-Q-induced mutations. However, BP-hydroquinone (BP-3,6-HQ) generated during the metabolic reduction of
BP-3,6-Q catalysed by NQO1 caused specific mutations involving the deletion of a single cytosine from the DNA sequence 5'-CCCCC-3' in
supF tRNA gene at a significantly high frequency. A similar cytosine deletion was also observed with benzoquinone hydroquinone (HQ),
indicating that the deletion of cytosine is associated with a hydroquinone class of compounds. These results suggest that: (1) quinones and
P450 reductase-activated products of quinones (semiquinones and ROS) are mutagenic compounds; (2) the mutational spectra of quinones,
semiquinones and hydroquinones differ from each other with respect to their mutational frequency and specificity; (3) NQO1 competes with
P450 reductase and protects the cells from quinone mutagenicity; and (4) the NQO1-metabolized quinones (hydroquinones), if not eliminated,
cause specific mutations that are not observed with quinones and P450 reductase-activated quinones (semiquinones and ROS).
Keywords: NAD(P)H:quinone oxidoreductase 1; P450 reductase; benzo(a)pyrene-3,6-quinone; mutagenicity
The aetiology of human cancer is quite diverse and exposure to
chemical carcinogens, particularly those present in the environ-
ment [e.g. benzo(a)pyrene (BP)] as contaminants, is responsible
for the majority of incidences of human cancer. BP has been
studied quite extensively as a prototype procarcinogen, whose
involvement in carcinogenesis after DNA adduct formation and
mutation has been fairly well documented (Gelboin, 1980;
Jernstrom and Graslund, 1994). BP undergoes oxidative metabo-
lism catalysed by cytochrome P450 lAI (CYP lAI) and
NADPH:cytochrome P450 reductase (P450 reductase) to generate
more than two dozen metabolites (Gelboin, 1980; O'Brien, 1991).
The most studied metabolite ofBP is benzo(a)pyrene-7,8-dihydro-
diol-9,10-epoxide (BPDE). BPDE binds with the deoxyguanosine
residues of DNA and causes mutations, preferably G:C -> T:A
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transversions, that accumulate in growth-regulatory genes leading
to carcinogenicity (Jermstrom and Graslund, 1994).
Another important class of BP metabolites generated during its
oxidative metabolism are the benzo(a)pyrene quinones (BP-3,6-Q,
BP-1,6-Q and BP-6,12-Q) (Gelboin, 1980; O'Brien, 1991).
Quinones, in general, are ubiquitously found in all aerobic plants
and animals and are present in the environment as part ofautomo-
bile exhaust, cigarette smoke and urban air particulates (O'Brien,
1991; Monks et al, 1992). Several compounds containing the
quinone nucleus are extensively used as anti-tumour drugs
(Workman, 1994). Because of their electrophilic nature and the
very high redox potential, the quinones are highly toxic (O'Brien,
1991; Monks et al, 1992; Workman, 1994). Despite being present
in significant amounts, thus posing a potential threat for extensive
human exposure, and being highly reactive and toxic, the mecha-
nisms underlying thetoxicity ofquinones, particularly with respect
to their mutagenic and carcinogenic potential, are rather poorly
understood. Earlier studies have shown that the fate of quinones
inside the cells depends on the balance between phase I
(cytochromes P450 and P450 reductase) enzymes that catalyse
metabolic activation of quinones, leading to cellular damage, and
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phase II [NAD(P)H:quinone oxidoreductase 1, glutathione S-
transferase and UDPG transferase) enzymes that catalyse meta-
bolic detoxification ofquinones, resulting in protection ofthe cells
(Talalay et al, 1995). Accordingly, it has been proposed that
induction of phase II enzymes by antioxidants, vitamins, isothio-
cyanates and related compounds leads to protection ofcells against
adverse effects of exposure to quinones and their precursors
(Prestera et al, 1993; Zhang et al, 1994; Talalay et al, 1995). Recent
studies in our laboratory on metabolic activation and detoxification
of BPQs (BP-3,6-Q, BP-1,6-Q and BP-6,12-Q) provided evidence
at the molecular level in support of the above hypothesis (Joseph
and Jaiswal, 1994). Accordingly, the one-electron reduction of
BPQ by P450 reductase resulted in the generation of
benzo(a)pyrene semiquinones (BPSQ) and reactive oxygen species
(ROS). The metabolites of BPQ (BPSQ and ROS) bind with the
deoxyguanosine residues of the DNA, as evident from the
generation ofBPQ (metabolites)-DNA adducts. On the otherhand,
NQOl competed with P450 reductase and catalysed two-electron
reduction and detoxification ofBPQ, thus protecting the cells from
the generation ofBPSQ, ROS and the corresponding DNA adducts.
In the present report, we have extended our studies on the muta-
genicity of the unmetabolized quinones and P450 reductase-
activated quinones (semiquinones and ROS) using BP-3,6-Q as the
model quinone and using the supFsuppressor tRNA gene ofthe E.
coli plasmid pUB3 as the mutational target to understand the geno-
toxic basis for the mutagenic and carcinogenic potential of
quinones. We also extended our studies to determine whether
NQOl exclusively reduces/prevents the mutagenicity of semi-
quinone and ROS or whether it also stimulates mutagenicity of
quinones. The various results obtained by us demonstrate that P450
reductase-activated BPQ (BPSQ and ROS) binding to the DNA
results in mutations (predominantly base deletions and substitu-
tions). We also demonstrate that these mutations are caused as a
result of the binding of ROS to the DNA. We further demonstrate
that NQOl reduces/prevents the mutations caused by P450 reduc-
tase-activated BPQ. In addition, we demonstrate that NQO1 catal-
yses the conversion of BPQ to BP hydroquinone (BPHQ), which
causes specific mutations involving deletion of a single cytosine
from the sequence 5'-CCCCC-3' at a very high frequency, which
was not observed with BPQ and P450 reductase-activated BPQ
(BPSQ and ROS). We further demonstrate that deletion ofa single
cytosine from the sequence 5'-CCCCC-3' is specifically associated
with the hydroquinone class of compounds. This is because, in
addition to BP-3,6-HQ, benzoquinone hydroquinone (HQ) also
causes similar mutations at high frequency. The quantitative and
qualitative aspects ofmutations due to BPQ as well as its one- and
two-electron reductive metabolites are compared with those due to
BPDE and the possible implications are discussed.
MATERIALS AND METHODS
Materials
The E. coli strain ES87 and the plasmid pUB3 carrying the muta-
tional target supF suppressor tRNA were obtained as a generous
gift from Dr E Loechler (Boston University, Boston, MA, USA).
DH5-a cells were purchased from Gibco-BRL (Gaithersburg,
MD, USA). Ingredients of the media used to grow the bacterial
cells and to select the mutants were purchased from Difco
Laboratories (Detroit, MI, USA). All other reagents used in the
experiments were of the highest purity available commercially.
The DNA sequencing kit version 2.0 was purchased from USB
Corporation, Cleveland, OH, USA. +(-)anti-BPDE and BP-3,6-
quinone were purchased from the Chemical Carcinogen
Repository of the National Cancer Institute (Kansas City, MO,
USA). Benzoquinone hydroquinone (HQ) was purchased from
Sigma Chemical Company, St Louis, MO, USA.
Construction of pMT2-cDNA recombinant plasmids,
transient transfection and enzyme assays
Human cDNAs encoding microsomal P450 reductase and cytosolic
NQO1 have been cloned and sequenced (Jaiswal et al, 1988;
Yamano et al, 1989). cDNAs for P450 reductase and NQOI were
separately subcloned into the unique EcoRl site of the expression
vector pMT2 (Shaw et al, 1991; Joseph and Jaiswal, 1994). The
pMT2, pMT2-P450 reductase and pMT2-NQO1 plasmids were
transiently transfected into monkey kidney COS1 cells in separate
experiments by the DEAE-dextran and chloroquine method to over-
express the respective proteins/activity (Shaw et al, 1991; Joseph
and Jaiswal, 1994). The transfected COS1 cells were harvested,
homogenized and subcellular-fractionated by procedures as
described (Joseph and Jaiswal, 1994). The whole homogenate and
microsomal and cytosolic fractions were analysed for P450 reduc-
tase and NQOI activities using methods as described (Joseph and
Jaiswal, 1994). Protein contents in the various fractions were esti-
matedusing Bradford's method (Bradford, 1976). The cytosolic and
microsomal fractions of transfected COSI cells were used as the
source ofP450 reductase and NQO1 enzymes, respectively, in incu-
bation mixtures to study the role of these enzymes in metabolic
reductive activation ordetoxification ofBP-3,6-Q, as determined by
analysis ofmutations in the supFtRNA region ofplasmid pUB3.
ES87 cells and pUB3 system to study mutations
caused by BPDE and BP-3,6-Q. Adduction of pUB3
DNA with BPDE, BP-3,6-Q and hydroquinone
pUB3 plasmid DNA, free from RNA and protein, was prepared
using the Qiagen plasmid preparation kit (Qiagen, CA, USA) and
further purified using phenol-chloroform extraction and ethanol
precipitation (Sambrook et al, 1989). For the DNA adduct forma-
tion, 10 ,ug ofpUB3 DNA was incubated with 100 ng ofBPDE in a
total volume of200 ,ul ofTris buffer, pH 7.4, in the dark for 2 h. In
the case of BP-3,6-Q-pUB3 DNA adducts, 1OgM BP-3,6-Q and
10 jg ofthe plasmid DNA were incubated either with the cytosolic
NQOl (15 ,ug oftotal protein) or with the microsomal P450 reduc-
tase (30 ,ug of total protein) and the co-factors required for the
enzymes to metabolize BP-3,6-Q (Joseph andJaiswal, 1994). In the
experiments involving the use of oxygen-free radical scavengers,
superoxide dismutase (SOD) and catalase were added into the reac-
tion mixture. The reaction mixture (200gl total volume) was incu-
bated at 370C for 2 h in the dark. The optimum conditions required
for the reductive metabolism of BP-3,6-Q catalysed by the
enzymes were obtained from preliminary experiments. At the end
of the incubation period, 25 jil of the reaction mixture was with-
drawn and used to estimate the amount of the cofactors (NADH in
the case ofNQOl and NADPH in the case of P450 reductase) that
remained unoxidized using the INT reagent (Nachlas et al, 1960).
pUB3 DNA was isolated and purified from the remaining reaction
mixture using phenol-chloroform extraction and ethanol precipita-
tion (Sambrook et al, 1989). The DNA was dried briefly under
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vacuum, resuspended in Tris-EDTA buffer and used to transform
competent ES87 cells. In similar experiments, BP-3,6-Q was
replaced with 15 gM hydroquinone solubilized in ethanol. In related
experiments, purified rat and human NQO1 enzymes were included
with hydroquinone for adduction with pUB3; this was to study the
role ofNQOl in further metabolism ofhydroquinone and its effect
on hydroquinone-induced mutagenicity.
Transformation of competent ES87 cells and selection
of the mutants
Competent ES87 cells were prepared and transformed either with
the control pUB3 DNA or that adducted with the BP metabolites,
according to the published procedures (Rodriguez and Leochler,
1993; Rodriguez et al, 1993). SOS induced (140 J m-2) and unin-
duced ES87 cells were transformed with 1 jg of the pUB3 DNA
by electroporation using the Gene Pulser (Bio-Rad, CA, USA) at
2.5 kV, 250 uF and 200 ohms according to the manufacturer's
instructions. The transformants were allowed to recover in SOC
medium for 1 h and plated on lactose minimal plates (LM plates)
after diluting appropriately to select the mutants growing as large,
blue colonies. The mutants were further screened by a second
round of selection on LM plates followed by melibiose minimum
(MM) plates, as described earlier (Rodriguez et al, 1993). A small
portion of the transformants was diluted and plated on LB plates
containing ampicillin to determine the total number of transfor-
mants. Mutation frequency (MF) was calculated on the basis ofthe
number of mutants growing on the MM plates and the total
number of the ampicillin-resistant transformants growing on the
LB plates. DNA was isolated from the mutant colonies growing on
the MM plates and used to transform competent DH5-ox cells.
Double-stranded DNA free of contaminating RNA and protein
was isolated from the DH5-x cells and was analysed for mutations
of the target supF tRNA gene by DNA sequencing. DNA
sequencing was performed with T7 DNA polymerase using the
sequenase kit version 2.0, according to the manufacturer's instruc-
tions. It may be noteworthy that every mutation was picked up
from a single transformation to avoid the generation of siblings of
individual mutations.
Competition between P450 reductase and NQ01 for
BP-3,6-Q metabolism and mutation
In order to assess the capacity of P450 reductase and NQO1 to
compete for the reductive metabolism ofBP-3,6-Q and to result in
mutation, the microsomes possessing P450 reductase and the
cytosol possessing NQO1 activity from the COS1 cells transfected
separately with the corresponding cDNAs were used. The enzyme
samples were mixed in different proportions and used in the incu-
bation mixture containing BP-3,6-Q, pUB3 DNA andthe cofactors
required for the reductive metabolism of BP-3,6-Q. In different
experiments, either the amount ofP450 reductase or that ofNQO1
was changed by keeping that ofthe other one constant. At the end
ofthe incubation period, DNA was isolated and used to transform
competent, SOS-induced ES87 cells, and the mutation frequency
was determined as described above.
RESULTS
Activities of microsomal P450 reductase and NQ01 in
untransfected and transfected monkey kidney COS1
cells
The microsomal P450 reductase and cytosolic NQO1 activities in
the untransfected and transfected monkey kidney COS1 cells are
shown in Table 1. The untransfected COS1 cells possessed an
undetectable amount ofendogenous NQO1 and a very low amount
of P450 reductase activity (Table 1; Joseph and Jaiswal, 1994).
The pMT2-P450 reductase-transfected COS1 cells produced 57-
fold higher P450 reductase activity than the untransfected
control cells. Similarly, the pMT2-NQO1-transfected COS1 cells
expressed 1192-fold higher NQO1 activity than the untransfected
COS1 cells. These higher activities of P450 reductase and NQO1
allowed us to use the corresponding subcellular fractions (micro-
somes for P450 reductase and cytosol for NQO1) for metabolic
reduction of BP-3,6-Q to study mutagenicity of quinones and the
role ofthese enzymes in quinone mutagenicity.
Mutation frequency
In general, mutation frequency, either spontaneous or that due to
the chemical modification ofthe pUB3 DNA, was higher (approx-
imately two- to threefold) in the SOS-induced cells than in those
that were not subjected to SOS induction (data not shown). With
the exception of the quantitative difference in mutation frequency,
no other change in response to the SOS induction ofthe ES87 cells
was noticed. Therefore, only those results obtained with the SOS-
induced ES87 cells are presented hereafter. In addition, the incuba-
tion of pUB3 DNA with BP-3,6-Q showed similar frequency and
type ofmutations as those observed with pUB3 + BP-3,6-Q mixed
and incubated with untransfected COS1 cell microsomes orcytosol
Table 1 Enzyme activities in untransfected and cDNA-transfected monkey kidney COS1 cells
Cells Microsomal cytochrome Cytosolic NOO1
P450 reductase (,umol of 2,6-dichlorophenolindophenol
(nmol of cytochrome c reduced min-' mg-' protein)
reduced min-' mg-' protein)
COS1 (untransfected) 16.34 ± 1.12 0.031 ± 0.002
COS1 + pMT2-human P450
reductase 925.00 ± 23.91 0.034 ± 0.001
COS1 + pMT2-human
NO01 17.22 ± 1.25 36.940 + 1.020
Cytosolic NQ01 activity was absent in microsomal fractions. Similarly, microsomal P450 reductase was absent in cytosolic fractions.
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Figure 1 A Mutation frequency of supFtRNA gene after transformation into SOS-induced ES87 cells. Control pUB3 DNA or DNA adducted with the
benzo(a)pyrene metabolites as described in the text were used to transform SOS-induced ES87 cells. Mutation frequency was determined as described in the
text. Data represent the mean ± s.e. of three independent experiments. (B) Role of microsomal P450 reductase in BP-3,6-Q mutagenicity. pUB3 DNA was
incubated with DMSO (pUB3) or BP-3,6-Q or BP-3,6-Q + COS1 cell microsomes (expressing endogenous levels of P450 reductase) or BP-3,6-Q + COS1 cell
microsomal fractions expressing 57-fold higher-levels of cDNA-derived P450 reductase, compared with untransfected COS1 cells expressing endogenous levels
of P450 reductase. In many cases purified SOD and/or catalase were combined with the COS1 cell microsomal fraction containing high levels of P450
reductase before incubation with pUB3 and BP-3,6-Q. After the incubations, the pUB3 DNA was isolated from the reaction mixture and used to transform SOS-
induced competent ES87 cells, and the mutation frequency was determined as described in the text. It may be noteworthy that the mutation frequency observed
with pUB3 + BP-3,6-Q was similar to the mutation frequency observed with pUB3 + BP-3,6-Q + COS1 microsomes from untransfected cells containing low
levels of P450 reductase. Therefore, data are shown only for pUB3 + BP-3,6-Q. Data represent the mean ± s.e. of three independent experiments
expressing endogenous (low to undetectable) levels ofP450 reduc-
tase and NQO1. Therefore, in all the experiments, we have shown
only results that were obtained with pUB3 + BP-3,6-Q.
The chemical modification ofthe pUB3 DNA with either BPDE
or BP-3,6-Q resulted in significant increases in the mutation
frequency compared with that of the spontaneous mutations with
the control (untreated) pUB3 DNA (Fig IA). The treatment of
pUB3 DNA with BPDE and BP-3,6-Q resulted in a sevenfold and a
fourfold increase, respectively, in the mutation frequency,
compared with the background mutation frequency. The metabolic
reductive activation of BP-3,6-Q by P450 reductase (one-electron-
reducing enzyme) further increased the mutation frequency ofBP-
3,6-Q by approximately twofold, compared with the unmetabolized
BP-3,6-Q, and by 8.2-fold, compared with the frequency ofsponta-
neous mutations (Figure iB). Interestingly, the pUB3 mutations
induced by P450 reductase-activated BP-3,6-Q were eliminated/
prevented by superoxide dismutase (SOD) and catalase (Figure
1B). Thirty units of SOD alone was less effective than 40 units of
catalase and a combination of 7.5 units of SOD with 10 units of
catalase (Figure 1B). The P450 reductase-activated BP-3,6-Q-
induced mutations in pUB3 were also significantly reduced as a
result ofthe inclusion ofNQO1 with P450 reductase in the metab-
olism of BP-3,6-Q (Figure 2A). Increasing the concentration of
NQOl with a constant concentration of P450 reductase showed
a NQOI concentration-dependent decrease in pUB3 mutations
caused by BP-3,6-Q (Figure 2A). In a similar experiment,
increasing the concentration of P450 reductase with a constant
concentration of NQOI increased the pUB3 mutations caused by
BP-3,6-Q (Figure 2B). The slow increase in mutation frequency
with increasing concentration of P450 reductase may be due to the
presence of large quantities ofNQO1, which is known to compete
with P450 reductase and to detoxify quinones (Figure 2B). In
another related experiment, the increase in the concentration of
NQOI caused steady but less significant decreases in BP-3,6-Q
(unmetabolized)-induced pUB3 mutations (Figure 2C). It may be
noteworthy that incubation of BPDE with P450 reductase and of
NQO1 individually and in combination had no effect on the muta-
tion frequency, compared with BPDE alone (data not shown).
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Figure 2 Competition between cytochrome P450 reductase and NQ01 to metabolize benzo(a)pyrene-3,6-quinone and its role in quinone mutagenicity. (A) pUB3
DNA was incubated with DMSO or BP-3,6-Q, a constant amount (30 jg of protein) of COS1 cell microsomes expressing high levels of P450 reductase and varying
amounts (jg of protein) of COS1 cytosolic extract expressing very high levels of NQ01. (B) pUB3 DNA was incubated with DMSO or BP-3,6-Q, a constant amount
(jg of protein) of COS1 cytosolic extract expressing very high levels of NQ01 and varying amounts (igg of protein) of COS1 cell microsomes expressing high levels
of P450 reductase. (C) pUB3 DNA was incubated with DMSO or BP-3,6-Q and varying amounts (gg of protein) of COS1 cytosolic extract expressing very high
levels of NQ01. In each case, afterthe incubation, the pUB3 DNA was isolated from the reaction mixture and was used to transform SOS-induced ES87 cells. The
mutation frequency was determined as described in the text. The data represent the mean ± s.e. of three independent experiments
Mutation spectra
The mutation frequencies ofthe various treatments ofpUB3 DNA
are shown in Table 2. The location of mutations by the various
agents used in the present study are shown in Figure 3. It is note-
worthy that only a portion of the total mutations from Table 2,
which includes all types ofmutations in proper ratios, are shown in
Figure 3. The analysis of mutation frequencies and the mutation
spectra ofthe different treatments showed that they were distinctly
different, suggesting the chemical specificity ofmutations (Table 2
and Figure 3).
Among spontaneous mutations (pUB3 alone), the single most
abundant mutation was the deletion of51 bp in theregion extending
from bp 68 to bp 119 of the supF tRNA gene. BPDE exhibited
a very high specificity for the G:C -* T:A transversion, which
accounted for 51% of all the mutations. It was found that the muta-
tional frequency of BPDE-induced G:C -* T:A transversions was
46-fold higher than spontaneous mutations. Fifty per cent ofBPDE-
induced G:C -4 T:A transversions was associated with the base G at
nucleotide position 15 ofthe supFtRNA gene ofthe pUB3 (Figure
3). Frameshift mutations were very rare in the case ofBPDE.
Unlike BPDE, the BP-3,6-Q and its metabolites frequently
caused frameshift mutations involving base deletions (Table 2). In
addition, they also caused base substitutions. The unmetabolized
BP-3,6-Q showed a several-fold higher frequency of similar muta-
tions, as observed in spontaneous mutations (Table 2). They did
not exhibit any strict mutational specificity, and therefore no muta-
tional hot spots were identifiable in this case. However, P450
reductase-activated BP-3,6-Q showed characteristic mutational
specificity (Table 2 and Figure 3). BP-3,6-Q reductively activated
by the P450 reductase showed a high preference for mutations
involving the base G (52% of all the mutations, mutational
frequency of 1.54). The most frequently observed mutations were
the deletion of base G from the DNA sequence 5'-GGGG-3'
between nucleotide positions 102-105 of the supF tRNA (muta-
tion frequency 0.70) and G:C -* A:T substitutions (mutation
frequency 0.76) (Table 2 and Figure 3; lane pUB3 + BP-3,6-
Q+P450 reductase). In addition, the P450 reductase-activated
metabolites ofBP-3,6-Q also caused other base substitution muta-
tions, including G:C -* C:G (frequency 0.56), G:C -* T:A (muta-
tion frequency 0.48), A:T -> G:C (mutation frequency 0.42) and
A:T -* T:A (mutation frequency 0.42) (Table 2 and Figure 3).
Interestingly, in the case of BP-3,6-Q metabolized by NQOI, the
mutation frequency of deletion of base G and all kinds of base
substitutions were significantly reduced compared with the P450
reductase-activated BP-3,6-Q (Table 2 and Figure 3). Accordingly,
the frequency of the deletion of base G was reduced from 0.70 in
the case of P450 reductase-activated BP-3,6-Q to 0.18 in the case
ofNQO1-metabolized BP-3,6-Q (Table 2). The frequency of base
substitutions was also significantly reduced in the presence of
NQO1; these included G:C -* T:A from 0.48 to 0.18, G:C -> A:T
from 0.76 to 0.12, G:C -- C:G from 0.56 to 0.12, A:T -* G:C from
0.42 to 0.24 and A:T -> T:A from 0.42 to 0.24 (Table 2). The only
mutational specificity observed in the case of BP-3,6-Q metabo-
lized by NQOl was a frameshift mutation involving deletion of a
single cytosine from the DNA sequence 5'-CCCCC-3' between the
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Table 2 Mutations detected in the supFtRNA gene of pUB3, both unadducted (spontaneous) and adducted with BPQ and BPQ metabolites,
after transformation into SOS-induced ES87 cells
pUB3 pUB3 pUB3 pUB3 pUB3
+BPDE +BP-3,6-Q +BP-3,6-Q +BP-3,6-Q
+ reductase + NO01
Total number of mutant colonies
selected from 65 x 106
transformed ES87 cells 40 (0.62) 176 (4.4) 110 (2.76) 178 (4.44) 96 (2.41)
Base substitutions
G:C-T:A 3 (0.05) 92 (2.3) 8 (0.20) 19 (0.48) 7 (0.18)
G:C-A:T 2 (0.03) 28 (0.7) 8 (0.20) 31 (0.76) 5 (0.12)
G:C-C:G 5 (0.08) 9 (0.23) 8 (0.20) 22 (0.56) 5 (0.12)
A:T - G:C 2 (0.03) 9 (0.23) 8 (0.20) 17 (0.42) 10 (0.24)
A:T -C:G 0 (0.00) 5 (0.12) 6 (0.14) 6 (0.14) 5 (0.12)
A:T - T:A 6 (0.09) 0 (0.00) 8 (0.20) 17 (0.42) 10 (0.24)
Deletions
G 1 (0.02) 0(0.00) 3(0.07) 28(0.70) 7(0.18)
A single C from
DNA sequence
5'-CCCCC-3' 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 24 (0.60)
C 0 (0.00) 0 (0.00) 3 (0.07) 0 (0.00) 0 (0.00)
T 3 (0.05) 0 (0.00) 6 (0.14) 6 (0.14) 7 (0.18)
A 1 (0.02) 0 (0.00) 0 (0.00) 0 (0.00) 5 (0.12)
AA 0 (0.00) 0 (0.00) 0 (0.00) 3 (0.07) 0 (0.00)
CCA 0 (0.00) 5 (0.12) 0 (0.00) 0 (0.00) 0 (0.00)
CCC 0 (0.00) 0 (0.00) 3 (0.07) 0 (0.00) 0 (0.00)
GGGTTCCCG 0 (0.00) 0 (0.00) 3 (0.07) 0 (0.00) 0 (0.00)
bp 68-119 15 (0.23) 9 (0.23) 33 (0.84) 39 (0.97) 17 (0.042)
bp 103-111 0 (0.00) 0 (0.00) 3 (0.07) 0 (0.00) 0 (0.00)
Insertions
C 0 (0.00) 9 (0.23) 3 (0.07) 0 (0.00) 0 (0.00)
Unclassified 3 (0.045) 14 (0.36) 17 (0.42) 5 (0.14) 0 (0.00)
Total number of
mutations detected 41 180 120 193 102
pUB3 DNA was treated with dimethyl sulphoxide (DMSO) or BPDE or BP-3,6-Q in the absence and presence of the enzymes. The adducted
DNA was isolated, cleaned, precipitated and used to transform SOS-induced E. cofiES87 cells. Mutants were isolated by procedures as
described (16-17). None of the mutations represent siblings because every mutation was picked from a single transformation. Note that the
total number of mutations detected is different to the total number of mutant colonies isolated. This is because, in a few cases, we detected
more than one mutation. Numbers in parentheses represent the mutation frequency (x 10-6 or 106 transformants). The mutants were isolated in
five independent experiments. The mutation frequency (x 10-6) is the average of the three most reliable experiments. The specific and
significant mutations are shown in bold numbers. Unclassified mutations included insertion of large fragments of DNA that were not
sequenced.
nucleotides 172 and 176 at a mutation frequency of0.60 (Table 2).
This deletion of a single cytosine from the DNA sequence of 5'-
CCCCC-3' was not observed in spontaneous mutations or muta-
tions caused by BPDE, unmetabolized BP-3,6-Q or P450
reductase-activated metabolic products ofBP-3,6-Q (semiquinone
and ROS). The results from previous studies and those from the
present report were used to generate a model to understand the role
of various enzymes in the metabolic activation, detoxification,
mutagenicity and possibly carcinogenicity ofBP-3,6-Q (Figure 4).
Hydroquinone mutagenicity
The mutational spectra of BP-3,6-HQ (generated as a result ofthe
two-electron reduction ofBP-3,6-Q catalysed by NQO1) was very
interesting, as described above. It caused specific deletion of a
single cytosine from the sequence 5'-CCCCC-3' in the supF tRNA
observed in spontaneous mutations and the mutations caused by
BP-3,6-Q and P450 reductase-catalysed metabolites of BP-3,6-Q
(BP-3,6-SQ and ROS) (Table 3). These observations raise three
very importantquestions. First, do otherhydroquinones also cause
similar mutations involving deletion of a single cytosine from
the DNA sequence 5'-CCCCC-3' as observed with BP-3,6-HQ?
Second, does BP-3,6-HQ undergo furthermetabolismcatalysedby
NQO1 to generate unidentified metabolites that cause deletion
mutation of a single cytosine? Third, does BP-3,6-HQ undergo
auto-oxidation by atmospheric oxygen to generate ROS that
causes specific deletion of a single cytosine from the sequence 5'-
CCCCC-3'? Several mutagenesis experiments were performed
with BP-3,6-HQ and a second hydroquinone, benzoquinone
hydroquinone (HQ), to address these questions (Table 3). HQ,
such as BP-3,6-HQ, caused specific deletion of a single cytosine
from the sequence 5'-CCCCC-3' of the supF tRNA gene.
gene at a high frequency. This type of deletion mutation was not However, the mutation frequency of cytosine deletion as a result
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
pUB3
ATG48ATGCGCCCCGCT60TCCCGATA_AGGG72A GCAGGGCCAGTA84AAAGCATTACCT96GTGGTGGGGTTC'08CCGAGCGGC
A T A T CC
AA AA TT C
AAA
AAAA
AAAAA
CAA120AGGaAGCAGACT132CTAAATCTGCCG144TCATCGACTTC1a56AAGGOTCGAATQ68UTTOCCCCACCA108CCATCA
G A T A T GA
G AA T G
Unclassified 3
...........................................................................................................................................................................................................
pUB3 + BPDE
ATG48ATGCGCCCCGCT60TCCCGATA AGGG72AGCAGGCCAGTA84AAAGCATTACCT96GTGGTGGGGTTC108CCGAGCGGC
A T TC
UTr ATTT
CAA120AGGGAGCAGACT132CTAAATCTGCCG144TCATCGACTTCG156AAGGTTCGAATC168CTTCCCCCAACCA180CCATCA
T C C TA A C TC AAA
TT A A C AC rrrr
Unclassified 3
...........................................................................................................................................................................................................
pUB3 + BP-3,6-Q
ATG48ATGCGCCCCGCT60TCCCGATA_AGGG72AGCAGGCCAGTA84AAAGCATTACCT96GTGGTGGGGTTC'08CCGAaQGCaGC
G A C AG A T TA
T AA AAA T C
AAAA CC
AAAAA
CAA120AGGAGAGQAGACT132CTAAATCTGCCG144TCATCGACTTCG'56AAGGTTCGAATC168CTTCCCCCACCA180CCATCA
CAA C C T T AA
AA
Unclassified 6
...........................................................................................................................................................................................................
pUB3 + BP-3,6-Q + P450 reductase
ATG48ATGCGCCCCGCT60TCCCGATA AGGG72AGCAGGCCAGTA84AAAGCATTACCT96GTGGTGGGG TTC108CCGAGCGGC
G A C A A
T AAAAA
AAAAA - CC
AAAAAA AA ccc
AAAAA
CAA120AGG GAGCAGACT132CTAAATCTGCCG144TCATCGACTT C G156AA G G TTCGAATC168C TTCCCCCACCA180CCATCA
A AC AA C C CA TT A
A C AT C A TT T
AA C TT U T
Unclassified 3
...........................................................................................................................................................................................................
pUB3 + BP-3,6-Q + NQ01
ATG48ATGCGCCCCGCT60TCCCGATA AGGG72AGCAGGCCAGTA84AAAGCATTACCT96GTGGTGGG G TTC108CCGAGCGGC
A A T AA T CC
AAA A T
AAA A
CAA120AGGGAGCAGACT'32CTAAATCTGCCG144TCATCGACTTCG156A A G G TICGAATC1QUTTCCCCQ A CCA18CCATCA
G C A A T A A
G C M T AAA
AAA
AAAA
Unclassified 0
...........................................................................................................................................................................................................
Figure 3 Mutational spectra of the supFtRNA gene of pUB3 DNA untreated and treated with chemicals and enzymes in SOS-induced ES87 cells. The
location of mutations by the various agents used in the present study are shown. It is noteworthy that only a portion of the total mutations from Table 2, which
included all types of mutations in proper ratios, are shown. The numbering used is similar to that reported earlier (16); the promoter is between bp 24 and 58,
the pre-tRNA is between bp 59 and 98 and the tRNA gene is between bp 99 and 183. The base undergoing mutation is underlined. A denotes deletion. The
mutational spectra of pUB3 + BP-3,6-Q in the absence and presence of COS1 cell microsomes expressing endogenous (low) activity of P450 reductase and
COS1 cell cytosol expressing undetectable levels of NQ01 were the same, therefore data are shown only for pUB3 + BP-3,6-Q
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Table 3 Frequency of BP-3,6-HQ- and HQ-induced deletion of a single cytosine from the sequence 5'-172CCCCC176-3' of the
SupFtRNA gene
Sample Frequency of cytosine deletion per 106
transformantsa
pUB3 alone (spontaneous mutations) 0.0
pUB3 + BP-3,6-Q 0.0
pUB3 + BP-3,6-Q + (COS1 microsomes) 0.0
pUB3 + BP-3,6-Q + [(COS1 + P450 reductase) microsomes]b 0.0
pUB3 + BP-3,6-Q + (COS1 cytosol) 0.0
pUB3 + BP-3,6-Q + [(COS1 + NO01) cytosol]c 0.60 ± 0.02
pUB3+HQ 0.30± 0.03
pUB3 + BP-3,6-Q + purified human NQOld 0.54 ± 0.03
pUB3 + BP-3,6-Q + purified rat NQOle 0.48 ± 0.02
pUB3 + HQ + purified human NQOld 0.36± 0.04
pUB3 + HQ + SOD (30 U) + catalase (40 U) 0.36± 0.03
Values represent mean ± s.e. of three independent experiments. aMutational spectra other than deletion of base C in all the cases
were more or less similar to the spontaneous mutations as shown in Figure 3 and Table 2. bCOS1 cells were transfected with
cDNA encoding NADPH:cytochrome P450 reductase. The transfected cells expressed a 57-fold higher amount of P450 reductase
activity, compared with untransfected COS1 cells as shown in Table 1. cCOS1 cells transfected with NQO1 cDNA. The cytosolic
fraction of transfected cells expressed 1192-fold higher levels of NQO1 activity, compared with the untransfected cells. dandeThe
purified human and rat NQO1 were obtained from Dr D Ross, School of Pharmacy, Denver, Colorado, USA. Both human and rat
NOO1 enzymes are known to catalyse high-affinity reduction of BP-3,6-Q to BP-3,6-HQ (6).
of HQ was 50% lower than that of BP-3,6-HQ (Table 3). The
results also demonstrate that further metabolism of BP-3,6-Q and
HQ with large amounts of purified human and rat NQO1 did not
show any significant increase in mutational frequency of deletion
of a single cytosine from 5'-CCCCC-3' in the supF tRNA region
of pUB3 DNA (Table 3). In addition, incubation of SOD and
catalase with HQ failed to decrease the frequency of deletion of
the cytosine (Table 3).
DISCUSSION
The multistep process of chemical carcinogenesis begins with the
metabolic activation of the procarcinogens to the ultimate, geno-
toxic metabolite(s) that interact with the DNA and other macro-
molecules, resulting in DNA and membrane damage (Guengerich,
1992). The presence of the unrepaired DNA damage during DNA
replication process results in cellular genetic changes influencing
the expression of growth-regulatory genes, culminating in the
genesis ofcancer (Harris, 1991). As metabolism ofthe procarcino-
gens is the pivotal step determining the ultimate genotoxic and
therefore the carcinogenic potential of the chemicals, selective
detoxification ofthe procarcinogenic chemicals by modulating the
activities of the detoxification enzymes has attracted much atten-
tion as a feasible chemopreventive mechanism (Talalay et al,
1988; Prochaska et al, 1992; Morse et al, 1993).
Quinones (e.g. benzo(a)pyrene quinones, benzoquinones and
naphthoquinones) belong to a class ofchemicals that are known to
cause cytotoxicity (O'Brien, 1991). However, the mutagenicity
and carcinogenicity of various quinones remain relatively
unknown. P450 reductase and NQO1 are the two most important
enzymes within the cells thatcatalyse activation and detoxification
ofquinones respectively (Joseph et al, 1994). It may also be note-
worthy that quinones are electrophilic compounds that can bind to
the DNA without undergoing enzymatic metabolism (O'Brien,
1991). For example, a quinone metabolite ofBP, the 7,8-quinone,
has been shown to form covalent adducts via Michael addition
with calf thymus DNA and the plasmid pGEM3 DNA without
further metabolism of the parent compound (Shou et al, 1993).
One-electron reductive activation ofquinones by enzymes, such as
P450 reductase, generates semiquinones and reactive oxygen
species (ROS) that have a high affinity for binding to the DNA
(O'Brien, 1991; Joseph et al, 1994; Talalay et al, 1995). On the
otherhand, two-electron reduction ofquinones by NQO1 results in
the formation of hydroquinones that are much more stable than
semiquinones and are removed by glucuronidation and other
conjugation reactions (O'Brien, 1991; Joseph et al., 1994; Lind,
1985; Talalay et al, 1995). Therefore, the NQO1 pathway of
metabolism of quinones is considered protective compared with
the P450 reductase pathway. Previously, we reported that P450
reductase-activated BP-3,6-Q (BP-3,6-SQ and ROS) binds specif-
ically to the deoxy guanosine residues ofthe DNA, resulting in the
formation of DNA adducts (Joseph and Jaiswal, 1994). We also
reported that NQO1 competed with the P450 reductase and specif-
ically prevented the binding ofP450 reductase-activated BP-3,6-Q
to the DNA (Joseph and Jaiswal, 1994).
In the present report, we demonstrated that binding ofunmetab-
olized and enzymatically metabolized BP-3,6-Q to the DNA was
mutagenic. The BP-3,6-Q-induced mutation frequency was 1.5-
fold lower than BPDE but fourfold higher than spontaneous
mutations. P450 reductase activated BP-3,6-Q into products
(BP-3,6-SQ and ROS) that further increased the mutation
frequency to eightfold higher than the spontaneous mutations.
Analysis of the mutation spectra revealed several characteristic
features concerning the mutational specificity ofBPDE, BP-3,6-Q
and the reductive metabolites ofBP-3,6-Q, including BP-3,6-SQ,
ROS and BP-3,6-HQ. In general, the mutation spectra of BPDE
was distinctly different from that of BP-3,6-Q and its reductive
metabolites. While BPDE resulted almost exclusively in basepair
substitution mutations, BP-3,6-Q and its reductive metabolites
caused both frameshift mutations, in particular deletions and base
substitutions. BPDE-induced G:C -+ T:A transversions and the
identification of a mutational hot spot at GI15 of the supF tRNA
gene were in agreement with previous reports (Rodriguez and
Leochler, 1993; Ruggeri et al, 1993).
British Journal ofCancer (1998) 77(5), 709-719 0CancerResearch Campaign 1998NQ01 reduces quinone mutagenicity 717
Carcinogenesis
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Mutagenicity (fourfold
higher than spontaneous)
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Benzo(a)pyrone-3,6quinone (BP-3,6-0)
A L NADPH: cytochrome
02 P450 reductase
02 I
NAD(P)H:
quinone
oxidoreductase
(NQO1)
Benzo(a)pyrene-3,6-sedroquinone (BP-3,6-HQ)
UDPGtransferase
? Glutathlone Stransferase Sulphotransferase
+2~SOD 0.2 -2 * H202 DetoxIfIcation
Catalase
2H202 2H20+02
De
(IT
Decreased mutations protection
Mutation frequency (per 106
transformants):
Total mutations (2.41)
Deletion of G (0.18)
G:C-oA:T (0.12)
G:C-*C:G (0.12)
G:C--+:A (0.18)
A:T-+G:C (0.24)
A:T-f:A (0.24)
eletion of C from the sequence 5'-CCCCC-3
nutation frequency 0.60)
Figure 4 Model for benzo(a)pyrene quinones mutagenicity and carcinogenicity. Three pathways of benzo(a)pyrene-3,6-quinone (BP-3,6-Q) activation and
detoxification are shown. First pathway involves direct binding of BP-3,6-Q to the DNA resulting in fourfold increase in mutagenicity of DNA, compared with
spontaneous mutations. However, no specificity of mutations are observed as a result of the direct binding of BP-3,6-Q to the DNA. In the second pathway, the
one-electron-reducing enzymes (e.g. P450 reductase) metabolically reduce the BP quinone (BP-3,6-Q) to semiquinone (BP-3,6-SQ), which enters in the redox
cycling to generate reactive oxygen species (ROS). The generation of semiquinone and ROS causes a further increase in mutation frequency, resulting in
specific mutations as shown. In the third pathway, the two-electron-reducing enzyme (e.g. NQO1) competes with P450 reductase and detoxifies BP-3,6-Q
resulting in reduction/prevention of P450 reductase-activated BP-3,6-Q-induced mutations. However, in this pathway, conversion of BP-3,6-Q to hydroquinone
(BP-3,6-HQ) by NOO1 also led to specific frameshift mutations involving deletion of a single cytosine from the sequence 5'-CCCCC-3'. This type of mutation
was not detected with BP-3,6-Q and P450 reductase-activated BP-3,6-Q (BP-3,6-SQ and ROS). Mutation frequencies (per 106transformants) are presented as
mean ± s.e. of three independent experiments
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Considerable differences in the mutational specificity were also
observed among unmetabolized BP-3,6-Q and its reductive
metabolites, suggesting that the actual mutagenic species in each
case may be different. In spite of its capacity to cause frameshift
mutations, the unmetabolized BP-3,6-Q did not show very high
specificity for any particular kind ofmutation, compared with the
spontaneous mutations. Unlike the parentcompound, the reductive
metabolites of BP-3,6-Q showed specific affinity for site- and
base-specific mutations. One-electron reductive activation of BP-
3,6-Q by P450 reductase into products (BP-3,6-SQ and ROS)
resulted in a very high affinity for mutations involving the base G.
This was expected based on the earlier observations (Shou et al,
1993; Joseph and Jaiswal, 1994) that the quinones exhibit very
high affinity for binding with the deoxy guanosine base of DNA.
The predominant base deletion was that of the base G. The
frequent base substitution mutations observed with the BP-3,6-Q
metabolized by P450 reductase were G:C -> A:T, G:C -4 C:G;
G:C -> T:A; A:T -* G:C and A:T -> T:A. Inhibition of the
increased mutagenicity of P450 reductase-activated BP-3,6-Q
(BP-3,6-SQ and ROS) by the scavengers of ROS indicated that
ROS generated during the metabolic activation of BP-3,6-Q by
P450 reductase was actually responsible for the increased muta-
genicity of BP-3,6-Q. This observation with BP-3,6-Q is also
supported by recent studies on mutagenicity of naphthoquinones
and benzoquinones using Salmonella strains sensitive to oxidative
mutagens (Hakura et al, 1994, 1995). The quinones, in general,
enter into redox cycling to produce semiquinones and ROS
(Figure 4). The ROS generated in the redox cycling causes oxida-
tive stress and DNA damage, including mutagenicity and possibly
carcinogenicity (Figure 4).
The failure of P450 reductase to enhance the mutagenicity of
BP-3,6-Q in the presence ofan excess amount ofNQO1 indicated
that NQO1 competed with P450 reductase forthe metabolic detox-
ification ofthe quinone, leading to the prevention ofonset ofredox
cycling and generation ofmutagenic semiquinones and ROS. The
products (hydroquinones) ofthe two-electron reduction ofBP-3,6-
Q catalysed by NQOl are quite stable in contrast to those of the
semiquinones generated by the P450 reductase and are detoxified
by glucuronidation, sulphation and/or glutathione conjugation
reactions (Figure 4). Thus, these results further confirm earlier
observations (Joseph and Jaiswal, 1994; Talalay et al, 1995)
suggesting that NQOI functions as a cellular control device
preventing the generation of semiquinones and the associated
oxidative stress so as to prevent the genotoxicity and possibly the
carcinogenicity ofBP-3,6-Q.
In summary, the results ofthe present study clearly indicate that
one-electron-reducing enzymes (e.g. P450 reductase) activate BP-
3,6-Q into metabolic products (semiquinones and ROS) that are
mutagenic and possibly carcinogenic (Figure 4). This conclusion
has two important implications. Firstly, the quinones are mutagenic
compounds and, secondly, the mutagenicity of BP is not only
caused by BPDE but also by BP-3,6-Q. The various results also
support the proposed chemopreventive role for NQO1 (Lind et al,
1982; Chesis et al, 1984; O'Brien, 1991; Monks et al, 1992; Joseph
and Jaiswal, 1994; Talalay et al, 1995) (Figure 4). However, a
careful analysis of the mutation spectra induced by metabolites of
BP-3,6-Q generated by NQOI suggests that further studies are
required to attribute an exclusive chemoprevention role for NQO1.
This is because BP-3,6-HQ, aproduct generated during the metab-
olism of BP-3,6-Q catalysed by NQO1, was not completely non-
genotoxic. The hydroquinone (BP-3,6-HQ) exhibited a very high
sequence-specific mutation, i.e. deletion of a single cytosine from
the sequence of 5'-CCCCC-3'. Similar deletion mutations were
also observed with another hydroquinone, i.e. benzoquinone
hydroquinone (HQ). The deletion of a single cytosine from the
sequence 5'-CCCCC-3', however, was not observed in sponta-
neous mutations and mutations with BP-3,6-Q and P450 reductase-
activated BP-3,6-Q (BP-3,6-SQ and ROS). This clearly suggests
that hydroquinones specifically cause deletion of a single cytosine
from the DNA sequence 5'-CCCCC-3'. In addition, the deletion of
cytosine is expected to be due to direct binding of hydroquinones
to the DNA because the frequency of mutations was unaffected
upon incubation of HQ with purified NQO1 and SOD + catalase.
Chemically induced base deletions and substitutions are known
to cause activation of oncogenes and inactivation of tumour-
suppressor genes, leading to tumour development (Balmain and
Brown, 1988; Hollstein et al, 1991; Vogelstein and Kinzler, 1992).
It is unclear, at this time, whether the hydroquinone-specific dele-
tion of cytosine will be observed in mammalian cells and will
survive the DNA repair process to play a role in oncogenesis. It is
especially important to study this in conditions in which hydro-
quinones may accumulate in cells as a result ofthe reduced/lack of
expression ofconjugating enzymes required for detoxification and
elimination ofhydroquinones from the cells.
ABBREVIATIONS
BP, benzo(a)pyrene; BPQ, benzo(a)pyrene quinone; BP-3,6-Q,
benzo(a)pyrene-3,6-quinone; BP-3,6-SQ, benzo(a)pyrene-3,6-
semiquinone; BP-3,6-HQ, benzo(a)pyrene-3,6-hydroquinone; BQ,
benzoquinone; HQ, benzoquinone hydroquinone; (+)-anti-BPDE,
(+)-,y-7,t-8-9,10-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene; ROS,
reactive oxygen species; SOD, superoxide dismutase; P450 reduc-
tase, microsomal NADPH:cytochrome P450 reductase; NQO1,
first form ofcytosolic NAD(P)H:quinone oxidoreductase
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